Clinical Trial Results:
Phase IV, single centre, randomised, open-label, two-period, two-way crossover clinical trial to assess the efficacy of Bilastine 20mg in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers under fasted and fed conditions.
Summary
|
|
EudraCT number |
2018-000913-19 |
Trial protocol |
ES |
Global end of trial date |
03 Jul 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jul 2022
|
First version publication date |
02 Jul 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
BILA-3818/PD
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
FAES Farma, S.A.
|
||
Sponsor organisation address |
Avda Autonomía, 10, Leioa, Spain, 48940
|
||
Public contact |
Clinical Research Director, FAES FARMA, S.A., 0034 944818300, ccampo@faes.es
|
||
Scientific contact |
Clinical Research Director, FAES FARMA, S.A., 0034 944818300, ccampo@faes.es
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
22 Sep 2021
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
03 Jul 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
03 Jul 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To compare the efficacy of Bilastine 20 mg administered orally under fasted and fed conditions (moderate-fat meal) in reduction of histamine-induced skin reactivity in healthy volunteers, taking into account the first treatment day (Day 1) and steady state (Day 4).
|
||
Protection of trial subjects |
Healthy volunteers, study designed to minimize the number of study drug administrations. All study subjects had immediate medical care access if necessary.
|
||
Background therapy |
Healthy volunteers, no additional therapies needed | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
17 May 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 24
|
||
Worldwide total number of subjects |
24
|
||
EEA total number of subjects |
24
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
24
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
A total of 41 subjects were screened for the trial and 29 subjects met the inclusion/exclusion criteria. Twenty-four subjects were randomized and 23 completed their participation on the clinical study. | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
The inclusion phase (four weeks before the beginning of experimental phase) was initiated and all subjects underwent a complete medical check-up in order to verify that they met all the inclusion criteria and none of the exclusion criteria. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Fed condition
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
Total population Fed | ||||||||||
Arm description |
Total population treated with bilastine once daily under fed conditions | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
Bilastine
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
20 mg once daily for 4 days under Fasting conditions
|
||||||||||
|
|||||||||||
Period 2
|
|||||||||||
Period 2 title |
Fasting condition
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
Total population Fasting | ||||||||||
Arm description |
Total population treated with bilastine once daily under fasting conditions | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
Bilastine
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
20 mg once daily for 4 days under fed conditions
|
||||||||||
|
|
||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||
Reporting group title |
Fed condition
|
|||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||
Subject analysis set title |
Pharmacodynamic profile
|
|||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | |||||||||||||||||||||||||||
Subject analysis set description |
Subjects who completed the clinical study without protocol deviations.
|
|||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Total population Fed
|
||
Reporting group description |
Total population treated with bilastine once daily under fed conditions | ||
Reporting group title |
Total population Fasting
|
||
Reporting group description |
Total population treated with bilastine once daily under fasting conditions | ||
Subject analysis set title |
Pharmacodynamic profile
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects who completed the clinical study without protocol deviations.
|
|
|||||||||||||
End point title |
Efficacy of bilastine 20 mg on 1st treatment day (Day 1) | ||||||||||||
End point description |
The primary objective of this study is to compare the efficacy of bilastine 20 mg administered orally under fasting and fed conditions (moderate-fat breakfast) in reduction of histamine-induced skin reactivity in healthy volunteers, taking into account the first treatment day (Day 1)
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 1
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
IBM-SPSS 22.0. | ||||||||||||
Comparison groups |
Total population Fed v Total population Fasting
|
||||||||||||
Number of subjects included in analysis |
46
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [1] | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
ANOVA | ||||||||||||
Confidence interval |
|||||||||||||
Notes [1] - Statistical analyses were performed using the program IBM-SPSS 22.0. In all the statistical analyses the level of significance was set at 5% (alpha value = 0.05), two-sided |
|
|||||||||||||
End point title |
Efficacy of bilastine 20 mg on steady state (Day 4) | ||||||||||||
End point description |
efficacy of bilastine 20 mg administered orally under fasting and fed conditions (moderate-fat breakfast) in reduction of histamine-induced skin reactivity in healthy volunteers, taking into account steady state (Day 4).
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 4
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
IBM-SPSS (v22.0) | ||||||||||||
Comparison groups |
Total population Fed v Total population Fasting
|
||||||||||||
Number of subjects included in analysis |
46
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
ANOVA | ||||||||||||
Confidence interval |
|
|||||||
End point title |
Safety and tolerability | ||||||
End point description |
To assess the safety and tolerability of bilastine after repeated (4 days) single daily oral dose (20 mg)
administration in young male and female healthy volunteers
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
From informed consent signature till final visit
|
||||||
|
|||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From informed consent signature till final visit
|
|||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||
Dictionary version |
21.0
|
|||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
Fasting
|
|||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||
Reporting group title |
Fed condition
|
|||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |